Bridge Pharmaceuticals' China Facility Receives Full AAALAC Accreditation: First Preclinical CRO with US and China Multispecies Capabilities

    GAITHERSBURG, MD., August 6 /CNW/ - Bridge Pharmaceuticals, Inc. (Bridge)
announced the awarding of full accreditation to its facility in Beijing, China
by the Council on Accreditation of the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC International). Bridge's
facility in Beijing (Vital Bridge (China), Inc.) is one of only seven
toxicology facilities in China to receive this recognition, and Bridge is the
first US-based company to offer toxicology services in multispecies at both
locations in the US and China. In the accreditation letter to Bridge dated
June 28, 2007, AAALAC International states, "The management and staff are
commended for providing quality facilities and programs for the care and use
of laboratory animals. Especially noteworthy were the institution's strong
administrative support for the animal care and use program as exemplified by
the high quality facilities, the extensive investment in training and
education of personnel, and the excellent teamwork noted among the staff (at
Bridge); as well as the extensive, well conceived, and thoroughly implemented
occupational health and safety program."

    Bridge's Maryland facility has long maintained AAALAC accreditation. More
than 30 countries recognize AAALAC accreditation as a demonstration of
responsible, ethical lab animal care. AAALAC accreditation now acknowledges
that Bridge's China facility also maintains animal laboratories with the
highest international standards.

    Bridge's China facility was purpose built to exacting specifications
(water systems, electricity, humidity control, HVAC, security, IT and data
management systems) and staffed with experienced, English-speaking
professionals. "Bridge has set the standard for China preclinical GLP labs,"
said Dr. Ada Kung, General Manager of Bridge's facility in Beijing. "The
AAALAC site inspectors cut no corners. They evaluated our overall physical
plant, our animal husbandry and housing, plus waste management, the labs, our
veterinary care, our procedures (SOP's), IACUC and policies, staff training
and education, our safety program--everything was scrutinized. Thanks to a
great team effort and hard work by everyone, the first AAALAC site visit
resulted in full accreditation. This is a monumental achievement."

    "AAALAC accreditation is what Bridge clients expect," added Bridge CEO
Tom Oakley. "They insist on preclinical drug development services that deliver
superior quality scientific data. Now, whether customers choose preclinical
drug development studies in our laboratories in the US or China, AAALAC
accreditation assures them we will deliver data quality of the highest order."

    Bridge Overview

    Bridge Pharmaceuticals, Inc. is one of the first preclinical contract
research organization (CRO) to provide US-level drug development services in
both Asia and the US. Bridge is headquartered in the United States with
laboratories in Gaithersburg, Maryland and Beijing, China. Bridge provides
cost-effective, FDA compliant drug development services for pharmaceutical,
biotech, and government clients. Bridge's capabilities in preclinical drug
development include GLP compliant toxicology, safety pharmacology, pathology,
and bioanalytical services. For more information, visit

For further information:

For further information: Bridge Pharmaceuticals, Inc. (USA) Marisa
Pawlewicz, 240-364-6249 or Bridge Pharmaceuticals,
Inc. (China) Tina Huang, 86-10-8072-8800

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890